logo
  Join        Login             Stock Quote

Verona Pharma plc: Analyst Presentation on the Company Website

Wednesday, April 10, 2013 1:20 PM


LONDON, April 10, 2013 /PRNewswire/ --

Verona Pharma plc

("Verona Pharma" or the "Company")

Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology company focused on developing novel treatments for chronic respiratory diseases, today presented its preliminary results to financial analysts in London. The presentation given is on the Company website.

Please visit http://www.veronapharma.com.

Notes to Editors

About Verona Pharma plc

Verona Pharma is developing first-in-class drugs to treat respiratory disease, such as COPD, asthma and chronic, severe cough. The Company has three drug programmes, two of which are in Phase II. The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties. VRP700 is an innovative product for suppressing chronic, severe cough in patients with underlying lung disease. In its third programme, Verona Pharma is investigating novel anti-inflammatory molecules, called NAIPs, for a wide range of respiratory and inflammatory diseases.


For further information please contact:


Verona Pharma
plc Tel: +44(0)20-7863-3300
Clive Page, Chairman 
Jan-Anders Karlsson, CEO 

 

WH Ireland Limited
 Tel: +44(0)20-7220-1666
Chris Fielding 
Nick Field 

 

FTI Consulting
 Tel: +44(0)20-7831-3113
Julia Phillips 
Simon Conway 

(Source: PR Newswire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.